Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04351347
Recruitment Status : Recruiting
First Posted : April 17, 2020
Last Update Posted : March 10, 2021
Sponsor:
Information provided by (Responsible Party):
Sherief Abd-Elsalam, Tanta University

Brief Summary:
Efficacy of Ivermectin in larger doses in COVID-19 treatment

Condition or disease Intervention/treatment Phase
COVID Drug: Ivermectin Phase 2 Phase 3

Detailed Description:
Clinical Study Evaluating the Efficacy of Ivermectin in higher doses in COVID-19 treatment

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Study Evaluating the Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment
Actual Study Start Date : June 16, 2020
Estimated Primary Completion Date : December 1, 2030
Estimated Study Completion Date : December 1, 2030

Resource links provided by the National Library of Medicine

Drug Information available for: Ivermectin

Arm Intervention/treatment
Experimental: Ivermectin
Ivermectin alone in larger doses
Drug: Ivermectin
ivermectin

No Intervention: Standard treatment
Standard of care treatment



Primary Outcome Measures :
  1. Number of patients with improvement or died [ Time Frame: 1 month ]
    The number of patients with improvement or death



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with covid 19

Exclusion Criteria:

  • Allergy or side effects to treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04351347


Contacts
Layout table for location contacts
Contact: Sherief Abd-Elsalam, ass. prof. 00201147773440 sheriefabdelsalam@yahoo.com

Locations
Layout table for location information
Egypt
Tanta University Recruiting
Tanta, Egypt, 35111
Contact: Sherief Abd-Elsalam         
Sponsors and Collaborators
Tanta University
Investigators
Layout table for investigator information
Principal Investigator: sherief Abd-Elsalam, Ass. Prof. Tanta University - Faculty of Medicine
Layout table for additonal information
Responsible Party: Sherief Abd-Elsalam, Ass. Prof. Tropical Medicine, Tanta University
ClinicalTrials.gov Identifier: NCT04351347    
Other Study ID Numbers: ivermecin covid
First Posted: April 17, 2020    Key Record Dates
Last Update Posted: March 10, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Ivermectin
Antiparasitic Agents
Anti-Infective Agents